Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
LONgitudinal and Integrated Evaluation of Biomarkers in reLation to phenotYpe in ALS
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive degeneration of upper and lower motor neurons, leading to paralysis and death.
- Trial name
- LONELYALS (NCT07312240)
- Testing
- Lumbar Puncture for analysis of Cerebrospinal Fluid, Deep Phenotyping, Routine blood chemistry analysis and genetic analysis
- Where
- Italy
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis
Assessing Perceptual Effects of Interactive Tasks
In this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (ALS) and age-matched speakers produced across interactive and non-interactive contexts with an…
- Trial name
- NCT06828523
- Testing
- Listener judgements of speech produced in different tasks
- Where
- United States
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Penn State University
Amyotrophic Lateral Sclerosis
Establishment of a Tissue Bank (Blood, CSF) for the Understanding of Motor Neuron Disease (MND)
Biomarkers are essential for the identification of disease states. There are no early diagnostic or prognostic markers for ALS. The purpose of this study is to identify a panel of biomarkers from blood or spinal fluid of ALS…
- Trial name
- WBC (NCT01950910)
- Where
- United States
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Amyotrophic Lateral Sclerosis
Developing a Discrimination Model to Diagnose ALS
To combine several brain imaging techniques to develop a new diagnostic test to help with earlier diagnosis of amyotrophic lateral sclerosis.
- Trial name
- NCT01995903
- Testing
- MRI(magnetic resonance imaging)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis
Repeated Mesenchymal Stem Cell Injections in ALS
An open-label, single-center clinical trial to evaluate the safety and efficacy of repeated intrathecal administrations of autologous bone marrow derived mesenchyme stem cells in ALS patients.
- Trial name
- NCT04821479
- Testing
- Mesenchymal stem cells (MSC)
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Amyotrophic Lateral Sclerosis
Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)
The study will evaluate the safety, tolerability and therapeutic effects of transplantation of escalating doses of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), in patients…
- Trial name
- NCT01777646
- Testing
- MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
- Where
- Israel
- Volunteers
- 14 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis, Respiratory Function
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
Thirty cases of amyotrophic lateral sclerosis patients were recruited from the neurology department of Ruijin Hospital, the pain department and the encephalopathy center of Luwan Branch of Ruijin Hospital.
- Conditions
- Amyotrophic Lateral Sclerosis, Respiratory Function, Scopolamine
- Trial name
- NCT04391361
- Testing
- Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
Amyotrophic Lateral Sclerosis
Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis
To verify the correlation between TMAO level and the pathogenesis and progression of ALS
- Trial name
- NCT04948346
- Testing
- diagnosed with ALS
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
ALS (Amyotrophic Lateral Sclerosis)
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07100119
- Testing
- LY4256984
- Where
- 12 sites in Belgium, Canada and 3 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis
Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis
During the course of ALS most patients develop swallowing deficits. In this pilot study we investigate if dysphagia in ALS can be improved by Pharyngeal Electrical Stimulation (PES).
- Trial name
- NCT03481348
- Testing
- Pharyngeal Electrical Stimulation
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Ulm
ALS (Amyotrophic Lateral Sclerosis)
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure.
- Trial name
- SLA (NCT02528071)
- Testing
- Diaphragmatic endurance test
- Where
- France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Amyotrophic Lateral Sclerosis (ALS)
FHND1002 for ALS Treatment: Phase 2
This is a Phase II clinical trial evaluating the effectiveness and safety of an investigational drug, FHND1002 granules, in adults with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- FHN-ALS2 (NCT07138014)
- Testing
- FHND1002 100mg, FHND1002 200mg
- Volunteers
- 180 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Amyotrophic Lateral Sclerosis
Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS
Amyotrophic lateral sclerosis (ALS) is a lethal degenerative disorder that upper motor and lower motor neurons are destroyed in brain stem and spinal cord. Riluzole is the only therapeutic option now.
- Trial name
- NCT02492516
- Testing
- mesenchymal stem cells
- Where
- Iran
- Volunteers
- 19 people
- Sponsor
- Royan Institute
Amyotrophic Lateral Sclerosis (ALS)
Trial of Safety and Efficacy of Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS)
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function.
- Trial name
- NCT01232738
- Testing
- rasagiline
- Where
- 10 sites in United States, Canada
- Volunteers
- 36 people
- Sponsor
- Yunxia Wang, MD
Amyotrophic Lateral Sclerosis, Multiple Sclerosis
Human Amniotic Mesenchymal Cell Secretome for Neurodegeneration and Neuroinflammation
Neurodegenerative diseases are debilitating conditions characterized by chronic inflammation, leading to dysfunction of both the non-neuronal cellular components of the central nervous system and peripheral blood immune cells.
- Trial name
- CONTRASTOME (NCT06551649)
- Testing
- Venous blood draw and skin biopsy
- Where
- 2 sites in Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Amyotrophic Lateral Sclerosis (ALS)
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality.
- Trial name
- tDCS-ALS (NCT06719947)
- Testing
- Active HD-tDCS, Simulated HD-tDCS
- Where
- 4 sites in Brazil, Chile
- Volunteers
- 80 people
- Sponsor
- Universidade Federal do Rio Grande do Norte
Amyotrophic Lateral Sclerosis
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALCALS (NCT06126315)
- Testing
- Acetyl-l-carnitine
- Where
- 19 sites in Australia, Italy
- Volunteers
- 246 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Amyotrophic Lateral Sclerosis
Metagenomic Characterization of the Intestinal Microbiota in ALS Patients and Association With Clinical Phenotypes
"Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving motor neurons in the cerebral cortex, brain stem and spinal cord.
- Trial name
- ALS-Gut (NCT06771414)
- Testing
- data collection
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
Open-label Clinical Trial of Lacosamide in ALS
Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT03186040
- Testing
- Lacosamide
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Chiba University